NeuBase Capital Surpluse vs Other Stockholder Equity Analysis

NBSE Stock

USD 0.44 0.02 4.76%

NeuBase Therapeutics financial indicator trend analysis is infinitely more than just investigating NeuBase Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NeuBase Therapeutics is a good investment. Please check the relationship between NeuBase Therapeutics Capital Surpluse and its Other Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.

Capital Surpluse vs Other Stockholder Equity

Capital Surpluse vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NeuBase Therapeutics Capital Surpluse account and Other Stockholder Equity. At this time, the significance of the direction appears to have no relationship.

The correlation between NeuBase Therapeutics' Capital Surpluse and Other Stockholder Equity is 0.03. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of NeuBase Therapeutics, assuming nothing else is changed. The correlation between historical values of NeuBase Therapeutics' Capital Surpluse and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of NeuBase Therapeutics are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Capital Surpluse i.e., NeuBase Therapeutics' Capital Surpluse and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.03

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Capital Surpluse

Other Stockholder Equity

Most indicators from NeuBase Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NeuBase Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.At present, NeuBase Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.22, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.17.

	2020	2021	2023	2024 (projected)
Cost Of Revenue	575.5K	1.3M	1.1M	1.1M
Research Development	14.4M	21.4M	19.3M	18.3M

Cost Of Revenue Research Development

NeuBase Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Cash	Inventory
Total Assets		0.59	0.45	0.79	0.93	0.6	-0.93	-0.44	0.56	-0.26	-0.38	0.94	0.39	-0.42	0.57	0.06	0.6	0.68	0.76	0.58	0.94	0.59	-0.41	-0.41	-0.17	-0.41
Short Long Term Debt Total	0.59		-0.11	0.5	0.34	1.0	-0.49	-0.48	0.0	-0.15	0.14	0.65	0.12	-0.19	0.95	-0.13	0.98	0.64	0.92	1.0	0.67	0.99	-0.19	-0.19	-0.04	-0.19
Other Current Liab	0.45	-0.11		0.74	0.47	-0.12	-0.2	-0.33	0.93	-0.28	-0.56	0.15	0.35	-0.34	-0.18	0.12	-0.17	0.38	0.25	-0.12	0.14	-0.1	-0.34	-0.33	-0.32	-0.34
Total Current Liabilities	0.79	0.5	0.74		0.65	0.5	-0.58	-0.53	0.71	-0.41	-0.38	0.61	0.45	-0.49	0.5	0.05	0.5	0.69	0.79	0.5	0.61	0.53	-0.49	-0.48	-0.36	-0.49
Total Stockholder Equity	0.93	0.34	0.47	0.65		0.36	-0.91	-0.32	0.6	-0.21	-0.49	0.87	0.38	-0.38	0.32	0.29	0.35	0.52	0.53	0.33	0.86	0.33	-0.38	-0.38	-0.15	-0.38
Property Plant And Equipment Net	0.6	1.0	-0.12	0.5	0.36		-0.52	-0.47	-0.01	-0.17	0.14	0.67	0.13	-0.2	0.96	-0.13	0.99	0.64	0.92	1.0	0.69	1.0	-0.2	-0.19	-0.04	-0.19
Net Debt	-0.93	-0.49	-0.2	-0.58	-0.91	-0.52		0.21	-0.28	0.27	0.36	-0.98	-0.35	0.36	-0.53	-0.08	-0.54	-0.47	-0.6	-0.49	-0.98	-0.48	0.36	0.36	0.1	0.36
Retained Earnings	-0.44	-0.48	-0.33	-0.53	-0.32	-0.47	0.21		-0.48	-0.4	0.17	-0.29	-0.46	0.49	-0.46	-0.12	-0.44	-0.93	-0.57	-0.48	-0.3	-0.51	0.49	0.48	0.45	0.49
Non Current Assets Total	0.56	0.0	0.93	0.71	0.6	-0.01	-0.28	-0.48		-0.07	-0.48	0.24	0.34	-0.34	-0.1	0.23	-0.07	0.52	0.32	-0.02	0.24	0.0	-0.34	-0.33	-0.28	-0.34
Non Currrent Assets Other	-0.26	-0.15	-0.28	-0.41	-0.21	-0.17	0.27	-0.4	-0.07		0.13	-0.27	0.13	-0.12	-0.16	0.07	-0.17	0.23	-0.29	-0.16	-0.27	-0.15	-0.12	-0.13	-0.21	-0.12
Other Assets	-0.38	0.14	-0.56	-0.38	-0.49	0.14	0.36	0.17	-0.48	0.13		-0.28	-0.81	0.78	0.16	-0.46	0.15	-0.23	-0.06	0.15	-0.27	0.16	0.78	0.78	0.73	0.78
Cash And Short Term Investments	0.94	0.65	0.15	0.61	0.87	0.67	-0.98	-0.29	0.24	-0.27	-0.28		0.33	-0.36	0.67	0.04	0.69	0.55	0.73	0.65	1.0	0.64	-0.35	-0.35	-0.09	-0.35
Net Receivables	0.39	0.12	0.35	0.45	0.38	0.13	-0.35	-0.46	0.34	0.13	-0.81	0.33		-0.99	0.18	0.32	0.15	0.49	0.27	0.12	0.33	0.14	-0.99	-0.99	-0.96	-0.99
Common Stock Total Equity	-0.42	-0.19	-0.34	-0.49	-0.38	-0.2	0.36	0.49	-0.34	-0.12	0.78	-0.36	-0.99		-0.25	-0.33	-0.22	-0.54	-0.33	-0.2	-0.36	-0.21	1.0	1.0	0.96	1.0
Common Stock Shares Outstanding	0.57	0.95	-0.18	0.5	0.32	0.96	-0.53	-0.46	-0.1	-0.16	0.16	0.67	0.18	-0.25		-0.11	0.98	0.62	0.88	0.96	0.69	0.97	-0.25	-0.24	-0.1	-0.24
Short Term Investments	0.06	-0.13	0.12	0.05	0.29	-0.13	-0.08	-0.12	0.23	0.07	-0.46	0.04	0.32	-0.33	-0.11		-0.11	0.03	-0.08	-0.13	0.03	-0.13	-0.33	-0.33	-0.31	-0.33
Non Current Liabilities Total	0.6	0.98	-0.17	0.5	0.35	0.99	-0.54	-0.44	-0.07	-0.17	0.15	0.69	0.15	-0.22	0.98	-0.11		0.61	0.91	0.99	0.71	0.99	-0.22	-0.22	-0.06	-0.22
Other Stockholder Equity	0.68	0.64	0.38	0.69	0.52	0.64	-0.47	-0.93	0.52	0.23	-0.23	0.55	0.49	-0.54	0.62	0.03	0.61		0.75	0.64	0.56	0.67	-0.54	-0.53	-0.43	-0.54
Total Liab	0.76	0.92	0.25	0.79	0.53	0.92	-0.6	-0.57	0.32	-0.29	-0.06	0.73	0.27	-0.33	0.88	-0.08	0.91	0.75		0.92	0.74	0.93	-0.33	-0.33	-0.17	-0.33
Property Plant And Equipment Gross	0.58	1.0	-0.12	0.5	0.33	1.0	-0.49	-0.48	-0.02	-0.16	0.15	0.65	0.12	-0.2	0.96	-0.13	0.99	0.64	0.92		0.67	1.0	-0.19	-0.19	-0.05	-0.19
Total Current Assets	0.94	0.67	0.14	0.61	0.86	0.69	-0.98	-0.3	0.24	-0.27	-0.27	1.0	0.33	-0.36	0.69	0.03	0.71	0.56	0.74	0.67		0.67	-0.36	-0.35	-0.09	-0.35
Short Term Debt	0.59	0.99	-0.1	0.53	0.33	1.0	-0.48	-0.51	0.0	-0.15	0.16	0.64	0.14	-0.21	0.97	-0.13	0.99	0.67	0.93	1.0	0.67		-0.21	-0.2	-0.06	-0.21
Common Stock	-0.41	-0.19	-0.34	-0.49	-0.38	-0.2	0.36	0.49	-0.34	-0.12	0.78	-0.35	-0.99	1.0	-0.25	-0.33	-0.22	-0.54	-0.33	-0.19	-0.36	-0.21		1.0	0.96	1.0
Accounts Payable	-0.41	-0.19	-0.33	-0.48	-0.38	-0.19	0.36	0.48	-0.33	-0.13	0.78	-0.35	-0.99	1.0	-0.24	-0.33	-0.22	-0.53	-0.33	-0.19	-0.35	-0.2	1.0		0.96	1.0
Cash	-0.17	-0.04	-0.32	-0.36	-0.15	-0.04	0.1	0.45	-0.28	-0.21	0.73	-0.09	-0.96	0.96	-0.1	-0.31	-0.06	-0.43	-0.17	-0.05	-0.09	-0.06	0.96	0.96		0.96
Inventory	-0.41	-0.19	-0.34	-0.49	-0.38	-0.19	0.36	0.49	-0.34	-0.12	0.78	-0.35	-0.99	1.0	-0.24	-0.33	-0.22	-0.54	-0.33	-0.19	-0.35	-0.21	1.0	1.0	0.96

Click cells to compare fundamentals

NeuBase Therapeutics Account Relationship Matchups

NeuBase Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.5M	34.4M	64.2M	32.7M	37.6M	39.5M
Short Long Term Debt Total	122.9K	138.6K	6.5M	6.0M	6.9M	7.2M
Other Current Liab	496.3K	950.2K	1.7M	1.7M	1.9M	2.0M
Total Current Liabilities	2.5M	3.1M	4.2M	4.2M	4.8M	5.0M
Total Stockholder Equity	10.0M	31.3M	54.1M	23.2M	26.7M	14.0M
Property Plant And Equipment Net	431.0K	1.2M	8.4M	7.8M	8.9M	9.4M
Net Debt	(10.2M)	(31.9M)	(46.4M)	(17.2M)	(19.7M)	(20.7M)
Retained Earnings	(27.0M)	(43.6M)	(69.0M)	(102.7M)	(92.5M)	(87.8M)
Non Current Assets Total	1.5M	1.6M	9.2M	8.0M	9.3M	5.5M
Non Currrent Assets Other	338.9K	145.3K	414.0K	273.2K	314.2K	298.5K
Cash And Short Term Investments	10.3M	32.0M	52.9M	23.2M	26.6M	28.0M
Common Stock Shares Outstanding	413.6K	981.0K	1.4M	1.6M	1.9M	2.0M
Liabilities And Stockholders Equity	12.5M	34.4M	64.2M	32.7M	37.6M	39.5M
Non Current Liabilities Total	1.6M	1.6M	5.9M	5.3M	6.1M	6.4M
Other Stockholder Equity	37.0M	74.9M	123.0M	125.9M	144.8M	152.1M
Total Liab	2.5M	3.1M	10.1M	9.5M	10.9M	11.5M
Property Plant And Equipment Gross	431.0K	1.2M	8.9M	9.1M	10.4M	10.9M
Total Current Assets	11.0M	32.8M	54.9M	24.6M	28.3M	29.8M
Short Term Debt	122.9K	138.6K	638.6K	660.7K	759.8K	797.8K
Common Stock	1.7K	2.3K	3.3K	3.3K	3.0K	2.8K
Accounts Payable	1.5M	1.5M	1.8M	1.8M	1.7M	1.6M
Cash	10.3M	32.0M	52.9M	23.2M	20.8M	19.8M
Other Current Assets	265.7K	294.6K	2.0B	1.5M	1.7M	1.6M
Net Tangible Assets	9.9M	31.3M	54.1M	23.2M	26.7M	22.1M
Property Plant Equipment	431.0K	1.2M	8.4M	7.8M	8.9M	9.4M
Short Long Term Debt	73.2K	122.9K	138.6K	148.4K	170.6K	124.2K
Net Invested Capital	10.2M	31.4M	54.2M	23.2M	26.7M	28.0M
Net Working Capital	8.5M	29.7M	50.7M	20.5M	23.6M	22.1M
Capital Stock	1.7K	2.3K	3.3K	3.3K	3.0K	2.6K

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NeuBase Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NeuBase Therapeutics' short interest history, or implied volatility extrapolated from NeuBase Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether NeuBase Therapeutics is a strong investment it is important to analyze NeuBase Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NeuBase Therapeutics' future performance. For an informed investment choice regarding NeuBase Stock, refer to the following important reports:

How To Invest In NeuBase

Details

Is NeuBase Stock a good investment?

Details

What is NeuBase Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for NeuBase Stock analysis

When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Fundamental Analysis View fundamental data based on most recent published financial statements
	CEOs Directory Screen CEOs from public companies around the world
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format

Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(18.60)

Return On Assets

(0.43)

Return On Equity

(0.93)

The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NeuBase Capital Surpluse vs Other Stockholder Equity Analysis

Capital Surpluse vs Other Stockholder Equity

Capital Surpluse vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Capital Surpluse

Other Stockholder Equity

NeuBase Therapeutics fundamental ratios Correlations

NeuBase Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NeuBase Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for NeuBase Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Short Term Debt	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity

Inventory	- 0.99	Net Receivables
Accounts Payable	- 0.99	Net Receivables
Common Stock	- 0.99	Net Receivables
Common Stock Total Equity	- 0.99	Net Receivables
Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt